相关实验视频

Updated: Jun 5, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

数学建模预测最佳的免疫检查点抑制剂和放射治疗组合以及给药时间

Shunsuke A Sakai^1,2,3, Koichi Saeki⁴, SungGi Chi¹

¹Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Cancer immunology research

|December 12, 2024

概括

将放射治疗与免疫检查点抑制剂相结合,在癌症治疗方面显示出有前途. 最佳的时间和药物组合,如抗PD-1/PD-L1或抗CTLA4/TIGIT,通过在治疗期间调节免疫反应来最大限度地提高疗效.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症研究癌症研究

背景情况:

放射治疗 (RT) 与免疫检查点抑制剂 (ICI) 结合是一种有前途的癌症治疗策略.
由于RT-ICI诱导的免疫变化的机制不清楚,RT-ICI治疗的最佳给药时间和药物组合尚未明确.

研究的目的:

在食道癌的放射治疗期间,研究淋巴细胞介导的分子相互作用的动态.
为了确定最佳的ICI组合和管理时间点,以提高RT疗效.

主要方法:

单细胞RNA测序和空间转录组学被用于分析患者组织样本.
开发了一个数学模型来预测不同RT时间点的ICI疗效.

主要成果:

在RT期间,淋巴细胞免疫反应从先天性转向适应性.
关键的配体-受体相互作用,包括PD-1-PD-L1,CTLA4-CD80/86和TIGIT-PVR,增加.
数学模型预测了与同时使用抗PD-1/PD-L1或同时/辅助抗CTLA4/TIGIT治疗的最大疗效.

结论:

同时或辅助ICI治疗,特别是抗PD-1/PD-L1,抗CTLA4或抗TIGIT,在与RT结合时显示出最大的潜力.
这些发现为研究优化RT-ICI组合和时间的临床试验提供了理由.
这项研究支持未来对新型治疗点和施用策略的研究.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...